Acyclovir (Fresenius Kabi USA, LLC)
Welcome to the PulseAid listing for the Acyclovir drug offered from Fresenius Kabi USA, LLC. This DNA Polymerase Inhibitors [MoA],Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Fresenius Kabi USA, LLC |
| NON-PROPRIETARY NAME: | ACYCLOVIR SODIUM |
| SUBSTANCE NAME: | ACYCLOVIR SODIUM |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | DNA Polymerase Inhibitors [MoA],Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | ANDA |
| START MARKETING DATE: | 2000-10-17 |
| END MARKETING DATE: | 0000-00-00 |
Acyclovir HUMAN PRESCRIPTION DRUG Details:
| Item Description | Acyclovir from Fresenius Kabi USA, LLC |
| LABELER NAME: | Fresenius Kabi USA, LLC |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 50(mg/mL) |
| START MARKETING DATE: | 2000-10-17 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 63323-325_d0f0fc50-cf59-4963-af54-a1fdc26aaa92 |
| PRODUCT NDC: | 63323-325 |
| APPLICATION NUMBER: | ANDA074930 |
Other ACYCLOVIR SODIUM Pharmaceutical Manufacturers / Labelers:
